Anita Huttner, MD
Associate Professor of PathologyCards
About
Research
Overview
Medical Research Interests
Cells; Central Nervous System; Central Nervous System Diseases; Embryonic Structures; Hemic and Immune Systems; Musculoskeletal Diseases; Neoplasms; Nervous System; Nervous System Diseases; Neuroglia; Neurons; Pathological Conditions, Signs and Symptoms; Pluripotent Stem Cells; Synapses; Tissues
Publications
2024
P27.10.B FACTORS INFLUENCING TIMELY DIAGNOSIS IN NEUROLYMPHOMATOSIS
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Huttner A, Fulbright R, Baehring J, Kaulen L. P27.10.B FACTORS INFLUENCING TIMELY DIAGNOSIS IN NEUROLYMPHOMATOSIS. Neuro-Oncology 2024, 26: v138-v139. PMCID: PMC11485484, DOI: 10.1093/neuonc/noae144.472.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemNerve root lesionsDiagnostic intervalRelapse of NHLSymptom onsetAssociated with early diagnosisTertiary referral centerAtypical clinical presentationRoot lesionsCerebrospinal fluid examinationDiagnostic work-upYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyClinical presentationReferral centerFluid examinationQuality control databaseDiagnostic delayFDG-PETPrimary diseaseUnivariate analysisConventional CTNeurolymphomatosisFactors influencing timely diagnosis in neurolymphomatosis
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Traub B, Galluzzo D, Huttner A, Fulbright R, Baehring J, Kaulen L. Factors influencing timely diagnosis in neurolymphomatosis. Journal Of Neuro-Oncology 2024, 170: 309-317. PMID: 39115616, DOI: 10.1007/s11060-024-04792-2.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemDiagnostic intervalNon-Hodgkin lymphoma diagnosisSymptom onset to diagnosisCerebrospinal fluid examinationYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyRare entityMedian intervalFluid examinationQuality control databaseDelayed diagnosisPrimary diseaseUnivariate analysisConventional CTDisease sitesNeurolymphomatosisNeuro-oncologyCancer CenterSecondary diseaseImaging modalitiesNeuroimaging findingsDiagnosisSingle-Cell Transcriptomic Analyses of Brain Parenchyma in Patients With New-Onset Refractory Status Epilepticus (NORSE)
Hanin A, Zhang L, Huttner A, Plu I, Mathon B, Bielle F, Navarro V, Hirsch L, Hafler D. Single-Cell Transcriptomic Analyses of Brain Parenchyma in Patients With New-Onset Refractory Status Epilepticus (NORSE). Neurology Neuroimmunology & Neuroinflammation 2024, 11: e200259. PMID: 38810181, PMCID: PMC11139018, DOI: 10.1212/nxi.0000000000200259.Peer-Reviewed Original ResearchConceptsNew-onset refractory status epilepticusTemporal lobe epilepsyGABAergic neuronsExcitatory neuronsInfiltrating macrophagesProportion of GABAergic neuronsChronic temporal lobe epilepsyRefractory status epilepticusInhibitory GABAergic neuronsSingle-cell transcriptome analysisDecreased expression of genesDegree of demyelinationImmune disturbancesNeuronal excitabilityImmune dysregulationNew-onsetStatus epilepticusPoor outcomeRefractory epilepsyHealthy childrenMicroglial reactivitySingle-nucleus RNA sequencingNLRP3 inflammasome activationInflammatory responseLobe epilepsyDifferentiation of IDH-mutant Glioma Subtypes Using Unsupervised Dimensionality Reduction of MRI Biomarkers
Willms K, Zeevi T, Chadha S, von Reppert M, Lost J, Tillmanns N, Merkaj S, Huttner A, Aneja S, Aboian M. Differentiation of IDH-mutant Glioma Subtypes Using Unsupervised Dimensionality Reduction of MRI Biomarkers. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2024 DOI: 10.58530/2024/3094.Peer-Reviewed Original ResearchReevaluating the Role of T2/FLAIR Mismatch Sign: Improving Diagnostic Accuracy With Qualitative MRI Features?
Willms K, von Reppert M, Lost J, Tillmanns N, Merkaj S, Huttner A, Schrickel E, Memon F, Aboian M. Reevaluating the Role of T2/FLAIR Mismatch Sign: Improving Diagnostic Accuracy With Qualitative MRI Features? Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2024 DOI: 10.58530/2024/3586.Peer-Reviewed Original ResearchT2/FLAIR mismatch signIDH-mutant gliomasT2/FLAIR-mismatchVASARI featuresDiagnostic accuracyAccurate preoperative diagnosisIDH-mutant astrocytomasAccurate patient managementQualitative MRI featuresImproving diagnostic accuracyPreoperative diagnosisIDH-mutantImproved diagnostic toolsMRI featuresEnhanced diagnostic methodMismatch signGlioma subtypesPatient managementGlioma cohortGliomaNoninvasive methodDiagnostic precisionDiagnostic methodsDiagnostic toolAstrocytoma
2023
Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas
Tillmanns N, Lost J, Tabor J, Vasandani S, Vetsa S, Marianayagam N, Yalcin K, Erson-Omay E, von Reppert M, Jekel L, Merkaj S, Ramakrishnan D, Avesta A, de Oliveira Santo I, Jin L, Huttner A, Bousabarah K, Ikuta I, Lin M, Aneja S, Turowski B, Aboian M, Moliterno J. Application of novel PACS-based informatics platform to identify imaging based predictors of CDKN2A allelic status in glioblastomas. Scientific Reports 2023, 13: 22942. PMID: 38135704, PMCID: PMC10746716, DOI: 10.1038/s41598-023-48918-4.Peer-Reviewed Original ResearchConceptsInformatics platformDeep learning algorithmsImaging featuresCDKN2A alterationsLearning algorithmHeterozygous lossHomozygous deletionLarge datasetsDeep white matter invasionGBM molecular subtypesNew informaticsQualitative imaging biomarkersWhole-exome sequencingQualitative imaging featuresGBM resectionRadiographic evidenceWorse prognosisPACSMolecular subtypesPial invasionImaging biomarkersCDKN2A mutationsAllele statusNoninvasive identificationMagnetic resonance imagesIntrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma
Khang M, Lee J, Lee T, Suh H, Lee S, Cavaliere A, Rushing A, Geraldo L, Belitzky E, Rossano S, de Feyter H, Shin K, Huttner A, Roussel M, Thomas J, Carson R, Marquez-Nostra B, Bindra R, Saltzman W. Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma. Science Translational Medicine 2023, 15: eadi1617. PMID: 37910601, PMCID: PMC11078331, DOI: 10.1126/scitranslmed.adi1617.Peer-Reviewed Original ResearchConceptsCerebrospinal fluidDelivery of drugsEffective therapyTherapeutic indexPARP inhibitorsBlood-brain barrierSite of tumorRapid systemic clearanceXenograft mouse modelSolvent evaporation processAdministration of substancesLeptomeningeal spreadIntrathecal deliveryLeptomeningeal metastasesBrain penetrationSystemic clearanceTumor regressionPolymer nanoparticlesMetastatic medulloblastomaMouse modelPediatric medulloblastomaDrug accumulationCSF turnoverEncapsulated drugsPET imagingChromosome instability and aneuploidy in the mammalian brain
Albert O, Sun S, Huttner A, Zhang Z, Suh Y, Campisi J, Vijg J, Montagna C. Chromosome instability and aneuploidy in the mammalian brain. Chromosome Research 2023, 31: 32. PMID: 37910282, PMCID: PMC10833588, DOI: 10.1007/s10577-023-09740-w.Peer-Reviewed Original ResearchConceptsChromosome instabilityExcess of chromosomesRole of aneuploidyNon-transformed cellsSomatic tissuesDiploid setChromosomal countsAneuploid cellsChromosomal alterationsMammalian brainCancer cellsAneuploidyCellsAging processChromosomesDevelopmental disordersPresent understandingSpecific consequencesDNAValuable insightsFuture research effortsBroad rangeHallmarkStructural modificationsP13.02.A APPLICATION OF NOVEL PACS-BASED INFORMATICS PLATFORM TO IDENTIFY IMAGING BASED PREDICTORS OF CDKN2A ALLELIC STATUS IN GLIOBLASTOMAS
Tillmanns N, Lost J, Tabor J, Vasandani S, Vetsa S, Marianayagam N, Yalcin K, Erson-Omay Z, von Reppert M, Jekel L, Merkaj S, Ramakrishnan D, Avesta A, de Oliveira Santo I, Jin L, Huttner A, Bousabarah K, Ikuta I, Lin M, Aneja S, Turowski B, Aboian M, Moliterno J. P13.02.A APPLICATION OF NOVEL PACS-BASED INFORMATICS PLATFORM TO IDENTIFY IMAGING BASED PREDICTORS OF CDKN2A ALLELIC STATUS IN GLIOBLASTOMAS. Neuro-Oncology 2023, 25: ii100-ii101. PMCID: PMC10489329, DOI: 10.1093/neuonc/noad137.336.Peer-Reviewed Original ResearchImaging featuresPial invasionQualitative imaging biomarkersQualitative imaging featuresWorse prognosisImaging biomarkersCDKN2A mutationsMethods Sixty-nine patientsCDKN2A alterationsHomozygous deletionHeterozygous lossSixty-nine patientsDeep white matterDeep white matter invasionGBM molecular subtypesWhole-exome sequencingNine patientsGBM resectionRadiographic evidenceMolecular subtypesBACKGROUND GliomasWhite matterAllele statusNoninvasive identificationGliomasP13.05.B INCORPORATION OF AI-BASED AUTOSEGMENTATION AND CLASSIFICATION INTO NEURORADIOLOGY WORKFLOW: PACS-BASED AI TO BUILD YALE GLIOMA DATASET
Tillmanns N, Lost J, Merkaj S, von Reppert M, Chadha S, Lin M, Bousabarah K, Huttner A, Aneja S, Avesta A, Omuro A, Aboian M. P13.05.B INCORPORATION OF AI-BASED AUTOSEGMENTATION AND CLASSIFICATION INTO NEURORADIOLOGY WORKFLOW: PACS-BASED AI TO BUILD YALE GLIOMA DATASET. Neuro-Oncology 2023, 25: ii101-ii101. PMCID: PMC10489908, DOI: 10.1093/neuonc/noad137.339.Peer-Reviewed Original Research
Clinical Trials
Current Trials
SV2A PET Imaging in Healthy Subjects and Epilepsy Patients
HIC ID1603017469RoleSub InvestigatorPrimary Completion Date05/01/2024Recruiting ParticipantsGenderBothAge18 years - 90 years
Academic Achievements & Community Involvement
Clinical Care
Overview
Anita Huttner, MD, is a pathologist who specializes in identifying diseases and cancers in the brain. “By looking at tumor cells under a microscope, I can see how they behave, which helps to shed light on their behavior in the brain as soon as they become tumor cells,” Dr. Huttner says.
In addition to her specialty in neuropathology, Dr. Huttner has studied molecular diagnostic pathology. “This means I can incorporate the genetic sequencing results of a brain tumor into my visual analysis of the tumor cells,” she says.
For her research, Dr. Huttner uses stem cells to “recreate the brain’s disorder found in diseases like epilepsy and Alzheimer’s disease.” Even though this research is in the early stages of development, she hopes to find better treatments for brain tumors soon. Dr. Huttner explains that she feels compelled to investigate brain tumors because her father died from one. “I feel for my patients,” she says.
At Yale School of Medicine, Dr. Huttner is an associate professor of pathology.
Clinical Specialties
Pathology; Neuropathology; Molecular & Genomic Pathology
News
News
- December 18, 2022
Yale Insights in Cardiovascular Medicine: 2022
- October 04, 2022
Yale Study Substantiates Impact of Aducanumab in Reducing Plaque Associated With Alzheimer’s
- May 02, 2022
Yale Pathology Diagnostic Pathology CME Annual Review Scheduled for September 17-18 at Yale Club of NYC
- May 28, 2021
Recent Research Sheds Light on Link Between Meningiomas and Seizures
Get In Touch
Contacts
Locations
Department of Pathology
Academic Office
Brady Memorial Laboratory
310 Cedar Street, Ste LH108C
New Haven, CT 06510
Clinical Inquiry
203.737.5601Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.